Merck, Inc.
🇺🇸United States
A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)
Phase 3
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 395
- Registration Number
- NCT00092352
A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)
Phase 3
Completed
- Conditions
- Postoperative Pain
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 251
- Registration Number
- NCT00092378
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)
Phase 3
Completed
- Conditions
- Postoperative Pain
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 125
- Registration Number
- NCT00092339
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
Phase 3
Completed
- Conditions
- Cervical CancerGenital Warts
- Interventions
- Biological: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2015-01-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3055
- Registration Number
- NCT00092495
Dose Confirmation Efficacy Study (V260-007)
Phase 3
Completed
- Conditions
- Rotavirus Infections
- Interventions
- Biological: RotaTeq™, rotavirus vaccine, live, oral, pentavalent
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2015-09-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1312
- Registration Number
- NCT00092443
A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED)
Phase 3
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 413
- Registration Number
- NCT00092365
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
Phase 3
Completed
- Conditions
- Genital WartsCervical Cancer
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3882
- Registration Number
- NCT00092482
A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
Phase 3
Completed
- Conditions
- VaricellaMeaslesMumpsRubella
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1997
- Registration Number
- NCT00092391
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
Phase 3
Completed
- Conditions
- MumpsRubellaVaricellaMeasles
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1200
- Registration Number
- NCT00092430
Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)
Phase 3
Completed
- Conditions
- Healthy
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 695
- Registration Number
- NCT00092417
© Copyright 2025. All Rights Reserved by MedPath